冠心病患者血清S100A12水平升高的临床意义

目的:检测冠心病(coronary heart disease,CHD)患者血清中S100A12含量,探讨其血清S100A12升高对冠心病风险的评估价值?方法:CHD组为明确诊断的冠心病患者128例,对照组为冠状动脉CTA或冠脉造影正常的患者61例,观察血清S100A12水平在两组间的变化,观察与冠脉病变的严重程度是否存在相关性?对包括血清S100A12高水平在内等危险因素进行Logistic回归?结果:冠心病患者组血清S100A12水平(43.57 ± 10.30)ng/ml]显著高于非冠心病患者组(25.63 ± 7.42)ng/ml],差异有统计学意义(P < 0.001),且与冠脉狭窄程度Gensini评分呈正相关(r = 0.391,P < 0.001);以冠心病发病为因变量,以年龄?男性?体质指数超标?高血压?糖尿病?血脂异常?血清S100A12高水平为自变量,结果发现,在排除了其他危险因素之后,血清S100A12高水平(OR = 2.67,P < 0.001)为冠心病相关的独立危险因素?结论:血清中S100A12水平可能是潜在的预测冠心病风险的生物学指标?

Serum level of S100A12 and its correlation in coronary heart disease

Objective: To investigate the serum level of S100A12 in coronary heart disease (CHD) patients and approach the effects of S100A12 in diagnosis of CHD. Methods: One hundred and twenty-eight patients who underwent CHD and sixty-one patients with normal coronary artery CTA or coronary angiography were selected in the study. Serum level of S100A12 was measured by ELISA assay. The relationship between serum level of S100A12 and the pathogenetic conditions of CHD were analyzed by logistic regression. Results: The serum level of S100A12(43.57 ± 10.30) ng/ml] in CHD group was significantly higher than those in serum of non-CHD group(25.63 ± 7.42) ng/ml](P < 0.001),and positively related with the coronary stenosis Gensini severity score (r = 0.391,P < 0.001). Further logistic regression analysis indicated that after ruling out the other risk factors,such as age,male,BMI overweight,high blood pressure,diabetes,and blood lipid abnormalities,S100A12 also had significant correlation with CHD (OR = 2.67,P < 0.001). Conclusion: The serum level of S100A12 may be a potential biological indicator to predict the risk for CHD.